Introduction
============

As a non-communicable disease, cancer is recognized as the main cause of human death worldwide in the 21st century and the biggest obstacle to prolong life span; in which digestive system carcinoma (DSC) including esophageal carcinoma, gastric cancer, hepatocellular carcinoma, pancreatic cancer, gallbladder cancer, and colorectal cancer, etc., play undoubtedly important roles. Global cancer statistics showed that the incidence of colorectal cancer ranked third among all cancers, followed by gastric cancer (fifth), liver cancer (sixth) and esophageal cancer (seventh), and ranked second, third, fourth and sixth respectively in terms of mortality[@B1]. Although some biomarkers, for instance HER2 and alpha fetoprotein, have been applied to the diagnosis and prognosis of DSC, sometimes their clinical applications were greatly limited due to poor specificity and tumors heterogeneity [@B2], [@B3]. Therefore, it is necessary to find novel biomarkers for more specific diagnostic and prognostic assessments.

Matrix metalloproteinases (MMPs) are essentially zinc-dependent endopeptidases existing in various tissues and more than 25 members are found currently in human beings [@B4], which are thought to play a key role in regulating metastasis and invasion and ultimately promoting tumor progression in a variety of cancers [@B5]-[@B7]. MMPs have been thought to degrade a variety of extracellular matrix components previously[@B8], [@B9], but studies in recent years have demonstrated that the function of MMPs can also involve in mediating extracellular, intercellular, and intracellular signaling pathways through complex interactions with multiple molecules[@B10]-[@B12].

Recently, considerable interest has been focused on the important MMP family members. The predictive effects of MMP-1, MMP-9, MMP-12, MMP-14, and MMP-15 on adverse clinical outcomes of primary tumors have been identified by large microarray analyses [@B13], and MMP-9, MMP-11, and MMP-15 have also been shown to be associated with poor survival in tumors [@B14]. None of these studies found any correlation between MMP and positive prognosis. Similarly, other studies reported the overexpression was closely linked to poor prognosis in nonsolid tumors [@B15], [@B16].

MMP-14 was the first characterized metalloproteinase in MMP family and naturally anchored to the cell membrane in an activated form. MMP-14, also known as the membrane-type MMP (MT1-MMP), have been shown to correlate with a variety of physiological functions and tumor-related behaviors such as migration [@B17], [@B18], invasion [@B17], [@B19], metastasis [@B17], [@B20], basement membrane remodeling [@B21], and angiogenesis [@B18], [@B20]. Notably in the tumorigenesis and progression of various DSC, MMP-14 plays a considerably complicated role. For instance, studies have shown that down-regulation of MMP-14 could inhibit invasion, migration and angiogenesis in gastric carcinoma [@B22], [@B23]. Researches by Li et al. have suggested that invasion and migration of hepatocellular carcinoma cells could be inhibited by targeting MMP-14[@B24]. Similar results can also be found in colorectal cancer [@B25], esophageal cancer [@B26], and pancreatic cancer [@B27]. Nevertheless, the other argued that the role of MMP-14 in the formation and tumor development was controversial [@B28]. It has been reported that MMP-14 could inhibit tumor angiogenesis by mediating the shedding of endoglin, thereby exerting a negative effect on tumor progression [@B29].

So far, there is not enough information on evidence-based medicine for prognostic significance of MMP-14 in DSC and the clinical application of targeting MMP-14 has also not been established yet. Therefore, we conducted this study to further clarify the part of MMP-14 plays particularly in the prognosis of DSC. Furthermore, we used GEPIA to provide differential expression between tumors and normal tissues and the evaluate the effect of MMP-14 expression on survival using 580 DSC patients with overall survival (OS) and disease free survival (DFS)/ progression-free survival (PFS) data.

Material and Methods
====================

This study was conducted based on the Meta-analysis of Observational Studies in Epidemiology (MOOSE) [@B30], Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines [@B31] and Population (patients with DSC), Intervention(Surgery), Comparator (expression levels), Outcomes (Survival) (PICO) methodology.

Search strategy
---------------

We carried out a systematic literature search using PubMed, PMC, EMBASE, Cochrane Library, Web of Science, Wanfang (Chinese) and CNKI (Chine se) database through August 6, 2019. The combination terms for retrieval were "tumor" or "carcinoma" or "cancer" and "Membrane type-1 matrix metalloproteinase or MT1-MMP, Matrix metalloproteinase-14 or MMP-14, Matrix metalloproteinases or MMPs" and "outcome" or "prognosis" or "survival" ([Supplementary Table 1](#SM0){ref-type="supplementary-material"}). To further identify potential articles, we also manually retrieved bibliography of relevant studies that were not retrieved by databases exploration.

Inclusion and exclusion criteria
--------------------------------

Inclusive criteria: (1) expression levels of MMP-14 in DSC tissue was assessed by immunohistochemistry (IHC), (2) associations between MMP-14 expression levels in DSC and OS, DFS/PFS or other possible survival parameters were described, (3) the expression of MMP-14 were categorized into low and high groups, (4) hazard ratios (HR) with 95% confidence interval (95%CI) for survival analysis were presented or could be reckoned from the instance data.

Exclusive criteria: (1) reviews, case reports, letters, expert opinions and meta-analysis, (2) articles without usable data to calculate the HRs and corresponding 95% CIs, (3) neither English nor Chinese language, (4) duplicate publications.

If a study overlaps data from other published literature, we choose to publish the latest one and/or the largest sample size.

Data extraction
---------------

The data of the following items were extracted from the eligible studies: Name of the first author, publication year, location of population, duration of follow-up, sample size, pathology subtypes, clinicopathological features, survival analyses results (univariate and/or multivariate analyses), HRs and *95% CI*s. Each study was considered as independent dataset. If *HRs* and *95% CIs* were not reported, they were extrapolated using the methods of Parmar [@B32] and Tierney [@B33].

Methodological quality assessment
---------------------------------

The methodological quality of eligible studies was evaluated by Newcastle-Ottawa Scale (NOS). NOS consists of three parts with a total of 9 points. Studies with NOS scores ≥ 6 points were considered as high-quality.

The specific Quality In Prognosis Studies (QUIPS) was assessed according to the method of Hayden et al [@B34]. Estimates of potential bias include study participation, study attrition, prognostic factor measurement, outcome measurement, study confounding, statistical analysis, and reporting.

MMP-14 expression profile and prognosis
---------------------------------------

GEPIA was used to evaluate the expression levels of MMP-14. GEPIA is an advanced interactive network server for analyzing the sequencing expression of RNA data of 9,736 cancers and 8,587 normal samples from the GTEx projects and TCGA, which are standard-based processing pipelines [@B35]. It offers customizable features such as differentially expressed tumor/normal analysis, profiling according to pathological stages, types of cancer, survival analysis, related analysis, similar gene detection, and analysis of dimensionality reduction. Kaplan-Meier (KM) curve was applied to assess the effect of MMP-14 on survival using 580 DSC patients with OS and DFS/PFS data.

Statistical analysis
--------------------

The combined HRs with 95% CIs was conducted by Review Manager 5.3.5 (Cochrane Collaboration, Oxford, UK) to evaluate the relationship between MMP-14 expression levels and prognosis. Indicators of inter-study heterogeneity were tested by the Q-tests and *I*-squared (*I*^2^) [@B36]. According to the results of heterogeneity analysis, when *P*-value of heterogeneity (*P*~heterogeneity~) ≥ 0.10 or *I*^2^ ≤ 50%, a fixed-effects model (Mantel-Haenszel method) [@B37] was applied to calculate the pooled effect size, otherwise (*P*~heterogeneity~ \< 0.1 and *I*^2^ \> 50%) the random-effects model (DerSimonian and Laird method)[@B38] was employed, and the sources of heterogeneity was explored by meta-regression in STATA 13.1MP (StataCorp, College Station, TX, USA) [@B39].

For articles that didn\'t provide HRs with 95% CIs or *P*-value, Engauge Digitizer 10.0 (<https://sourceforge.net/projects/digitizer/>) was utilized to extract the original survival data from the KM curves. Subgroups analyses were conducted by evaluation methods of survival analysis, indicators of prognosis, and cancer subtypes (pathological type). Begg\'s [@B40] and Egger\'s test [@B41] were used to explore the publication bias in STATA 13.1MP.

If the 95% CI did not cover 1 and the pooled *HR* \> 1, a statistical significance was considered. All *P*-values were two-sided and *P* \< 0.05 was considered statistically significant. The KM plotter split is median, and the MMP-14 expression profile from DSC samples and paired normal tissues.

Results
=======

Identification of the eligible studies
--------------------------------------

A flow diagram of the literature search strategy was summarized in Figure [1](#F1){ref-type="fig"}, and a total of 2,064 records were retrieved from databases. By screening the titles and/or abstracts, we excluded 1,172 duplicates, 677 unrelated records or articles in languages other than English and Chinese, and 215 were further identified and screened, then retrieved 94 relevant full-text articles. 75 articles were further removed because of non-DSC or the samples were not detected in protein expression levels or were not derived from tissue. Finally, 20 eligible articles [@B42]-[@B61] were included in this meta-analysis (Table [1](#T1){ref-type="table"}).

Baseline characteristics of eligible studies
--------------------------------------------

The basic characteristics of included studies were presented in Table [1](#T1){ref-type="table"}. They were published from 2007 to 2019 and consist of 2,519 patients with OS and 438 patients with DFS/PFS from China and Japan. The study was based on the location of subjects to determine the country of study. The cancer types included gastric cancer, esophageal squamous cell carcinoma (ESCC), colorectal cancer (CRC), oral cancer, hepatocellular carcinoma (HCC), gallbladder carcinomas (GBC), and pancreatic cancer. The samples were all tissues and the methods of detection were IHC. The cut-off values of MMP-14 were immunohistochemistry score (HIS) and percentage of positive cells (PPC), most with HIS.

Methodological quality assessment
---------------------------------

According to QUIPS, the quality assessment for eligible studies was summaried in Table [2](#T2){ref-type="table"}. The risk of bias domains legend was presented in Figure [2](#F2){ref-type="fig"}. According to NOS ([Supplementary Table 2](#SM0){ref-type="supplementary-material"}), yielded scores ranging from 5 to 9, with a mean score of 7.05, 90.00% (18/20) of these studies were considered as high-quality (quality score≥6).

Expression in DSC tissue
------------------------

The heterogeneity of MMP-14 for OS was at the critical value of the statistics (*P*~heterogeneity~ = 0.01 and *I*^2^ = 48%). According to the preconditions, the fixed effect was applied to calculate the combined HRs for MMP-14. Overall, the pooled analysis of the 17 studies indicated that MMP-14 expression was significantly associated with OS (HR = 1.98, 95% Cl: 1.76-2.22, *P* \< 0.001) and DFS/PFS (HR = 3.61, 95% Cl: 2.39-5.43, *P* \< 0.001) (Table [3](#T3){ref-type="table"}).

Subgroup analysis was carried out based on statistical approach, and the results revealed that high MMP-14 expression in both log rank (HR = 1.86, 95% CI: 1.57-2.28, *P* \< 0.001) and multivariate analysis (HR = 2.64, 95% CI: 1.95-3.58, *P* \< 0.001) were significant associated with poor OS (Table [3](#T3){ref-type="table"}). Meanwhile, stratified analysis based on cut-off value showed the high expression of MMP-14 for IHS (HR = 2.18, 95% CI: 1.69-2.81, *P* \< 0.001) and PPC (HR = 2.48, 95% CI: 1.92-3.20, *P* \< 0.001) were statistically significant with the poor OS, respectively.

According to cancer subtype, we conducted subgroup analysis of gastric cancer, ESCC, colorectal cancer, HCC and other types, respectively. It revealed a significant correlation between increased MMP-14 and poor OS in gastric cancer patients (HR = 2.21, 95% CI: 1.76-2.77, *P* \< 0.001), ESCC (HR = 2.01, 95% CI: 1.58-2.57, *P* \< 0.001), HCC (HR = 2.14, 95% CI 1.35-2.19, *P* \< 0.001), oral cancer (HR = 1.69, 95% CI: 1.30-3.20, *P* \< 0.001) and other types of DSC (HR = 3.10, 95% CI 1.06-9.03, *P* \< 0.001). For subgroups analyses, there was no heterogeneity among subgroups (𝐼^2^ = 0%, 𝑃 = 0.90) (Table [3](#T3){ref-type="table"}).

Test of heterogeneity
---------------------

Nineteen OS related datasets displayed the critical value of the statistics heterogeneity (*P*~heterogeneity~ = 0.01 and *I*^2^ = 48%). To ensure the robustness and statistical effectiveness of the results, meta-regression was employed to investigated sources of heterogeneity for OS, including year of publication, cancer types, ethnicity (Asians or Caucasians), language (English or Chinese), sample size (100 as the boundary), cut-off and follow-up. The result revealed that there was no altered by above characteristics (Table [4](#T4){ref-type="table"}).

Sensitivity analysis and publication bias
-----------------------------------------

To verify the robustness of our results, sensitivity analysis was performed by removing one study at a time and recalculating pooled HR. The results did not substantially alter the combined HR, indicating that this meta-analysis was reliable. ([Supplementary Figure 1](#SM0){ref-type="supplementary-material"}).

The funnel plots shape was basically symmetrical ([Supplementary Figure 2](#SM0){ref-type="supplementary-material"}), and Begg\'s and Egger\'s tests indicated that there is no substantial publication bias ([Supplementary Table 3](#SM0){ref-type="supplementary-material"}).

MMP-14 expression profile and prognosis
---------------------------------------

The median expression of tumor (red dots) and normal (green dots) samples were presented in Figure [3](#F3){ref-type="fig"}. Each dot represents a sample expression level, Gene expression profiles consist of various tumor tissues and paired normal tissues. The results indicated that the MMP-14 expression level in DSC tissues was significantly higher than that in normal tissues ([Supplementary Table 4](#SM0){ref-type="supplementary-material"}).

For OS, a highly significant correlation was revealed between high MMP-14 expression level and poor prognosis (HR = 2.2, *P*\<0.001) (Figure [4](#F4){ref-type="fig"}A). Similarly, MMP-14 expression was significantly associated with DFS (HR = 1.8, *P* \< 0.001) (Figure [4](#F4){ref-type="fig"}B).

Discussion
==========

Over the last few years, overexpression of MMP-14 has been proved to be an independent prognostic factor for several cancers, its prognostic significance is adverse [@B62]. However, the clinical prognostic significance of MMP-14 is still not characterized in DSC. Thus, this meta-analysis was performed to provide more accurate evidence for the prognostic value of MMP-14 in patients with DSC. Then, the expression data of cancer and paired normal tissues from GTEx projects and TCGA was used to illustrate our result.

The accumulated evidence indicates that members of the MMP protein family are related to the progression and tumorigenesis including metastasis and invasion of various cancers, and ultimately affect patient survival. MMP-14 was the first membrane type MMP discovered, it is a member of membrane-type MMP and participates in many biological processes due to its ability to promote angiogenesis and matrix degradation [@B63]. Changing the MMP-14 level may leads to the rearrangement of cytoskeleton and invasion and migration [@B28].

In this study, we only included the studies that examined the MMP-14 expression in tissues (tumor and paired normal tissues) by immunohistochemistry to ensure the reliability and consistency our results. We found that high expression of MMP-14 may be an independent poor prognostic factor (OS, HR = 1.98, 95% Cl: 1.76-2.22, *P* \< 0.001 and DFS/PFS, HR = 3.61, 95% Cl: 2.39-5.43, *P* \< 0.001), particularly in multivariate analysis group (HR = 2.64, 95% CI: 1.95-3.58, *P* \< 0.001), and patients with gastric cancer (HR = 2.21, 95% CI: 1.76-2.77, *P* \< 0.001) and HCC (HR = 2.14, 95% CI: 1.35-2.19, *P* \< 0.001) and oral cancer(HR = 1.69, 95% CI: 1.30-3.20, *P* \< 0.001). Our findings of gastric cancer were consistent with another similar study [@B64], nevertheless, no correlation was observed between the MMP-14 expression and the prognosis of colorectal cancer.

In order to be able to infer reliable results, we first tested the prognostic significance of MMP14 in the GTEx projects and TCGA, and then verified our results in these two databases. In the GTEx projects, the MMP-14 expression in DSC tissues was significantly higher than that in normal tissues, Moreover, we used the 580 paired DSC and normal tissues from the TCGA database with OS and DFS data, the MMP14 expression in DSC was significantly higher than that in normal control group. All these findings are further confirmed our conclusion, and indicated that MMP-14 may be an independent prognostic factor for both OS and DFS/PFS in patients with DSC.

MMP-14 promotes angiogenesis by promoting the expression of vascular epidermal growth factor and releasing biologically active extracellular matrix products [@B65]. MMP-14 is overexpressed in most human cancer, and the published studies have demonstrated that overexpression of MMP-14 in various cancers is associated with poor prognosis [@B66]. Our findings of cancer subtype analysis were consistent with this study.

MMP-14 has been showed to be activated by TGFβ1, and then plays a complex role in tumor formation, angiogenesis and invasion through destruction and reconstruction of the basement membrane [@B67].TGFβ1 signaling promotes migration, progression and growth of the late carcinomas. Amara et al. found that stimulation of soluble factors secreted by cancer cells activates MMP-14. One of the effectors is TGFβ1, which differentiates fibroblasts in the matrix and stimulates MMP-14 expression and activation [@B68]. The published studies of MMP14 focused on angiogenesis and tumor invasion [@B69], [@B70]. Previous studies have shown MMP-14 was highly expressed in different tumor tissues, and its expression could promote the migration, invasion and metastasis of tumor cells *in vitro* and *in vivo* [@B71]. Potentially, MMP14 may play a crucial role in different biological processes of cancer and normal tissues [@B72].

Although our main results are robust, there are some limitations. Firstly, not all eligible studies provide multivariate adjusted HRs, so, a portion of HRs with the 95% CIs were extracted from survival curves. Although we have subgroup analysis based on statistical approach, these calculated might be generated several tiny errors. Secondly, the algorithms of cut-off values of MMP-14 expression were different, which may lead to deviation of the true values. Thirdly, although there was no statistical evidence of publication bias, most eligible studies are in China, which may lead to publication bias. Finally, bioinformatics analyses need to be validated by more experimental and biological study. Despite these limitations, this study about association between MMP-14 and DSC prognosis was certainly warranted.

In conclusion, our study provided the first evidence of MMP-14 in the prognosis of DSC, which strongly suggested that MMP-14 has potential in prediction of treatment outcomes and may be a potential independent prognostic factor in DSC. Furthermore, high-quality and multicenter clinical studies should be carried out to further clarify the significance of MMP-14 in survival outcomes of DSC.
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![Kaplan-Meier survival curves for OS and DFS according to MMP-14 expression in patients with DSC. OS (A) and DFS (B) of patients with high vs. low MMP-14 expression are shown.](jcav11p1141g004){#F4}

###### 

Clinicopathological characteristics of eligible studies.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Author                 Year   Country   Ethnicity   Number   Histology   Tumor stage         Follow-up\     Cut-off   Analysis   Outcome          
                                                                                               (Months)                                             
  ---------------------- ------ --------- ----------- -------- ----------- ------------------- -------------- --------- ---------- ---------------- -------
  Cui et al [@B42]       2019   China     Asian       218      DFS,218     Colorectal cancer   TNM (NA)       60        IHS≥4      Cox regression   HR/SC

  Xu et al [@B43]        2019   China     Asian       80       PFS,80      Oral cancer         TNM, I-IV      120       IHS≥4      Kaplan-Meier     SC

  Bi et al [@B44]        2018   China     Asian       83                   Oral cancer         TNM, I-IV      100       IHS≥3      Kaplan-Meier     SC

  Wang et al [@B45]      2017   China     Asian       204                  ESCC                TNM, I-Ⅲ       120       IHS≥6      Kaplan-Meier     SC

  Zhang et al [@B46]     2017   China     Asian       142                  ESCC                TNM(NA)        84        HIS\>4     Cox regression   HR/SC

  Zheng et al [@B47]     2017   China     Asian       68                   Pancreatic cancer   TNM, I-IV      50        IHS≥4      Kaplan-Meier     SC

  Naseh et al [@B48]     2016   Iran      Caucasian   96                   Gastric Cancer      TNM I-IV       150       IHS≥4      Cox regression   HR/SC

  Zheng et al [@B49]     2016   China     Asian       50                   Gastric cancer      TNM I-IV       60        PPC≥25%    Cox regression   HR/SC

  Dong et al [@B50]      2015   China     Asian       205                  Gastric cancer      TNM I-IV       100       IHS≥5      Cox regression   HR/SC

  Liu et al [@B51]       2015   China     Asian       95                   Gastric Cancer      NA             60        PPC≥25%    Kaplan-Meier     SC

  Akanuma et al [@B52]   2014   Japan     Asian       140      DFS,140     ESCC                TNM, I-IV      120       PPC≥25%    Cox regression   HR/SC

  Bao et al [@B53]       2014   China     Asian       90                   Colorectal cancer   Dukes\'stage   81        IHS≥3      Cox regression   HR

  Liu et al [@B54]       2014   China     Asian       102                  HCC                 NA             60        PPC≥20%    Kaplan-Meier     SC

  He et al [@B55]        2013   China     Asian       205                  Gastric Cancer      TNM I-IV       100       IHS\>4     Cox regression   HR/SC

  Peng et al [@B56]      2013   China     Asian       184                  Gastric cancer      TNM I-IV       108       PPC≥25%    Cox regression   HR/SC

  Sun et al [@B57]       2013   China     Asian       89                   GBC                 NSS, S1-S5     60        IHS(NA)    Cox regression   HR/SC

  Yang et al [@B58]      2013   China     Asian       243                  Colorectal cancer   Dukes\'stage   108       IHS\>4     Cox regression   HR/SC

  Wu et al [@B59]        2012   China     Asian       95                   ESCC                NA             60        PPC≥20%    Kaplan-Meier     SC

  Huang et al [@B60]     2009   China     Asian       61                   HCC                 NA             60        IHS≥2      Cox regression   HR/SC

  Vicente et al[@B61]    2007   Spain     Caucasian   69                   Oral cancer         TNM, I-IV      132       IHS≥3      Kaplan-Meier     SC
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

HCC, hepatocellular carcinoma; ESCC, esophageal squamous cell carcinoma; GBC, gallbladder carcinomas; DFS, disease free survival; HR, Hazard ratio; SC, survival curve; IHS, immunohistochemistry score; NSS, Nevin stage system; PPC, Percentage of positive cells.

###### 

Quality assessment of included studies based on the Quality In Prognosis Studies (QUIPS).

  Study                  Quality evaluation of prognosis study   Total Score^a^   Level of Evidence^b^                                  
  ---------------------- --------------------------------------- ---------------- ---------------------- -------- -------- -------- --- ----
  Cui et al [@B42]       Yes                                     Partly           Yes                    Yes      Partly   Yes      9   1b
  Xu et al [@B43]        Yes                                     Partly           Yes                    Partly   Partly   Partly   6   2b
  Bi et al [@B44]        Yes                                     Partly           Yes                    Partly   Partly   Partly   8   2b
  Wang et al [@B45]      Partly                                  Partly           Yes                    Yes      Partly   Partly   7   2b
  Zhang et al [@B46]     Yes                                     Partly           Yes                    Yes      Partly   Yes      8   2b
  Zheng et al [@B47]     Partly                                  Partly           Yes                    Yes      Partly   Partly   7   2b
  Naseh et al [@B48]     Partly                                  Partly           Yes                    Yes      Partly   Yes      5   2b
  Zheng et al [@B49]     Partly                                  Partly           Yes                    Yes      Partly   Yes      7   2b
  Dong et al [@B50]      Partly                                  Partly           Yes                    Yes      Partly   Yes      7   2b
  Liu et al [@B51]       Partly                                  Partly           Yes                    Partly   Partly   Partly   7   2b
  Akanuma et al [@B52]   Partly                                  Partly           Yes                    Partly   Partly   Partly   5   2b
  Bao et al [@B53]       Partly                                  Partly           Yes                    Yes      Partly   Partly   7   2b
  Liu et al [@B54]       Partly                                  Partly           Yes                    Partly   Partly   Partly   7   2b
  He et al [@B55]        Partly                                  Partly           Yes                    Yes      Partly   Yes      9   2b
  Peng et al [@B56]      Yes                                     Partly           Yes                    Yes      Partly   Yes      6   2b
  Sun et al [@B57]       Yes                                     Partly           Yes                    Yes      Partly   Yes      6   2b
  Yang et al [@B58]      Yes                                     Partly           Yes                    Yes      Partly   Yes      6   2b
  Wu et al [@B59]        Partly                                  Partly           Yes                    Partly   Partly   Partly   7   2b
  Huang et al [@B60]     Partly                                  Partly           Yes                    Yes      Partly   Yes      8   2b
  Vicente et al[@B61]    Yes                                     Partly           Yes                    Yes      Partly   Partly   9   2b

^a^ Quality assessment of included studies based on the Newcastle-Ottawa Scale.^b^ The levels of evidence were estimated for all included studies with the Oxford Centre for Evidence Based Medicine criteria.

###### 

Main results of pooled HRs in the meta-analysis.

  ----------------------------------------------------------------------------------------------------------------------------------------
  Comparisons                    Heterogeneity test   Summary HR\   Hypothesis test   Model              Studies                      
                                                      (95% CI)                                                                        
  ------------------------------ -------------------- ------------- ----------------- ------------------ --------- --------- -------- ----
  Total (High vs. Low)                                                                                                                

  OS                             36.29                0.01          48                1.98(1.76,2.22)    11.58     \<0.001   Fixed    20

  DFS/PFS                        2.38                 0.30          16                3.61(2.39,5.43)    6.14      \<0.001   Fixed    3

  OS                                                                                                                                  

  *Analysis*                                                                                                                          

  Log rank (KM)                  4.05                 0.77          0                 1.86(1.57,2.28)    7.17      \<0.001   Fixed    8

  Multivariate analysis (Cox)    31.16                0.001         65                2.64(1.95,3.58)    6.26      \<0.001   Random   12

  *Cut-off*                                                                                                                           

  IHS                            31.61                0.002         62                2.18(1.69,2.81)    6.02      \<0.001   Random   13

  PPC                            0.12                 0.99          0                 2.48(1.92,3.20)    6.95      \<0.001   Fixed    6

  *Cancer subtypes*                                                                                                                   

  Gastric Cancer                 1.29                 0.94          0                 2.21(1.76,2.77)    6.90      \<0.001   Fixed    6

  ESCC                           5.06                 0.17          41                2.01(1.58,2.57)    5.60      \<0.001   Fixed    4

  Colorectal cancer              15.89                0.00          87                4.16(0.93,18.56)   1.87      0.06      Random   3

  Oral cancer                    0.38                 0.83          0                 1.69(1.30,2.20)    3.96      \<0.001   Fixed    3

  HCC                            0.23                 0.63          0                 2.14(1.35,2.19)    3.26      \<0.001   Fixed    2

  Other types                    6.05                 0.01          83                3.10(1.06,9.03)    2.07      0.04      Random   2

  Test for subgroup difference   1.06                 0.90          0                                                                 
  ----------------------------------------------------------------------------------------------------------------------------------------

KM, survival data from a Kaplan-Meier curve; Cox, survival data from a multivariate Cox regression analysis; Other types of cancer include Pancreatic cancer and gallbladder carcinomas; IHS, immunohistochemistry score; PPC, Percentage of positive cells.

###### 

The results of heterogeneity test.

  Comparisons        Coef.    Std. Err.   *t*     *P*     95% CI
  ------------------ -------- ----------- ------- ------- --------------
  Publication year   0.172    0.315       0.55    0.593   -0.751-0.408
  Cancer types       0.020    0.094       0.21    0.836   -0.185-0.214
  Language           -0.172   0.266       -0.65   0.531   -0.751-0.408
  Ethnic             0.205    0.562       -0.37   0.721   -1.428-1.018
  Cut-off            0.007    0.328       0.02    0.983   -0.707-0.721
  Follow up          -0.577   0.605       -0.95   0.360   -1.990-0.742
  Sample size        -0.383   0.293       1.31    0.215   -0.254-1.020

[^1]: Competing Interests: The authors have declared that no competing interest exists.
